Dr Harald Enzmann, CHMP Chairman
European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

17th July 2020

Subject: Withdrawal of RAYOQTA (abicipar pegol) 16mg/mL solution for injection;
EMA procedure reference: EMEA/H/C/005103

Dear Dr Harald Enzmann

I would like to inform you that, at this point of time, Allergan Pharmaceuticals International Limited has taken the decision to withdraw the application for Marketing Authorisation of RAYOQTA (abicipar pegol) 16mg/mL solution for injection, which was intended to be used for:

- Treatment of neovascular (wet) age-related macular degeneration (AMD) in adult patients.

This withdrawal is based on the following reason:

- Allergan Pharmaceuticals International Limited had decided to discontinue this application since the major objections raised cannot be resolved within the available time frame.

There are no ongoing clinical trials and no EU compassionate use programmes with abicipar pegol, therefore it is not expected that this withdrawal will have any consequences on European patients.

Allergan Pharmaceuticals International Limited would like to sincerely thank the (Co) Rapporteurs, EMA, PRAC and the CHMP for their time dedicated to reviewing this application and the valuable support and helpful guidance providing during the review process.

Allergan Pharmaceuticals International Limited reserves the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMA website.

Yours sincerely

On behalf of Allergan Pharmaceuticals International Limited

Allergan Limited
Marlow International
Parkway
Marlow,
Buckinghamshire
SL7 1YL
UK

T +44 (0) 1628 494 444
F +44 (0) 1628 494 449
www.allergan.com